Caspofungin disk diffusion breakpoints and quality control

Journal of Clinical Microbiology

Volumn 46, Issue 6, 2008, Pages 1927-1929

  Brown, Steven D ^a   Traczewski, Maria M ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN;

ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CANDIDA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISK DIFFUSION; FUNGUS ISOLATION; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SPECIES COMPARISON; STANDARDIZATION;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; CULTURE MEDIA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL;

CANDIDA;

EID: 45149086122     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00279-08     Document Type: Article

References (20)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41:2333-2338.
2. Abruzzo, G. K., C. J. Gill, A. M. Flattery, L. Kong, C. Leighton, J. G. Smith, V. B. Pikounis, K. Bartizal, and H. Rosen. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. 45:2310-2318.
3. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2000. Quality control limits for broth microbiology susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
4. Clinical and Laboratory Standards Institute. 2001. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline. Document M23-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline. Document M44. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2006. Quality control minimal inhibitory concentration (MIC) limits for broth microdilution and MIC interpretive breakpoints. Supplement. M27-S2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility tests of yeasts. Approved standard. Document M27-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2006. Zone diameter interpretive standards and corresponding minimal inhibitory concentration (MIC) interpretive breakpoints. Supplement. M44-S2. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Dodgson, K. J., A. R. Dodgson, C. Pujol, S. A. Messer, D. R. Soll, and M. A. Pfaller. 2005. Caspofungin-resistant C. glabrata. Clin. Microbiol. Infect. 11(Suppl. 2):364.
10. Gavan, T. L., R. N. Jones, A. L. Barry, P. C. Fuchs, E. H. Gerlach, J. M. Matsen, L. B. Reller, C. Thornsberry, and L. D. Thrupp. 1981. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study. J. Clin. Microbiol. 14:67-72.
11. Hernandez, S., J. L. Lopez-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383.
12. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
13. MacCallum, D. M., and F. C. Odds. 2004. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrob. Agents Chemother. 48:4911-4914.
14. Moudgal, V., T. Little, D. Boikov, and J. A. Vazquez. 2005. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49:767-769.
15. Nelson, P. W., M. Lozano-Chiu, and J. H. Rex. 1997. In vitro growth-inhibitory activity of pneumocandins L-733,560 and K-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. J. Med. Vet. Mycol. 35:585-587.
16. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
17. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.
18. Rex, J., M. Pfaller, J. Galgiani, M. Bartlett, A. Espinel-Ingroff, M. Ghannoum, M. Lancaster, F. Odds, M. Rinaldi, T. Walsh, and A. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro and in vivo correlation data for caspofungin and itraconazole and Candida infections. Clin. Infect. Dis. 24:235-247.
19. Rex, J. H., T. J. Walsh, J. D. Sobel, S. G. Filler, P. G. Pappas, W. E. Dismukes, and J. E. Edwards. 2000. Practice guidelines for treatment of candidiasis. Clin. Infect. Dis. 30:662-678.
20. Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1612-1614.